Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Spexis AG
  6. News
  7. Summary
    POLN   CH0106213793

SPEXIS AG

(POLN)
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Polyphor AG Announces Executive Changes

10/29/2021 | 01:15am EST

Polyphor AG announced that Subject to the closing of the merger, Andreas Walln?fer, Silvio Inderbitzin and Hugh O'Dowd have announced their intention to resign from the Board as of such closing. For such event, the shareholders elected Dennis Ausiello, Dan Hartman and Robert Clarke as new members of the Board of Directors and Jeffrey D. Wager as new member and Chairman of the Board of Directors, each for the term until the next Annual Shareholders' Meeting. In addition, and again subject to closing of the merger, the shareholders elected Kuno Sommer, Dan Hartmann and Robert Clarke as the members of the compensation committee, each for the term until the next Annual Shareholders' Meeting.


ę S&P Capital IQ 2021
All news about SPEXIS AG
2021Polyphor Finalizes Merger With EnBiotix, to Change Name to Spexis
MT
2021Polyphor closes merger with EnBiotix and is renamed Spexis
EQ
2021EnBiotix, Inc. completed the acquisition of Polyphor AG from Novartis Venture Funds, Va..
CI
2021EnBiotix, Inc. Closes $11M Pre-Merger Financing
AQ
2021Polyphor To Close EnBiotix Merger Before 2021-End
MT
2021Polyphor to inform about the financing of its merger partner EnBiotix
EQ
2021Polyphor Treats First Patient in Early-Stage Study of Inhaled Antibiotic
MT
2021Polyphor and EnBiotix announce dosing of first patient in a first-in-human clinical tri..
EQ
2021Polyphor and Enbiotix Announces Dosing of First Patient in a First-In-Human Clinical Tr..
CI
2021Polyphor, EnBiotix Shareholders Green-Light Merger, Name Change
MT
More news
Chart SPEXIS AG
Duration : Period :
Spexis AG Technical Analysis Chart | POLN | CH0106213793 | MarketScreener
Technical analysis trends SPEXIS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Managers and Directors
G÷khan Batur Chief Executive Officer
Hernan Levett Chief Financial Officer
Kuno Sommer Chairman
Frank T. Weber Chief Medical & Development Officer
Bernard Bollag Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SPEXIS AG6.59%92
CSL LIMITED-11.13%88 612
WUXI BIOLOGICS (CAYMAN) INC.-13.88%43 139
SAMSUNG BIOLOGICS CO.,LTD.-16.17%41 851
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-8.47%32 258